ID   TBK1_HUMAN              Reviewed;         729 AA.
AC   Q9UHD2; A8K4S4; Q8IYV3; Q9NUJ5;
DT   20-DEC-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   10-MAY-2017, entry version 156.
DE   RecName: Full=Serine/threonine-protein kinase TBK1;
DE            EC=2.7.11.1;
DE   AltName: Full=NF-kappa-B-activating kinase;
DE   AltName: Full=T2K;
DE   AltName: Full=TANK-binding kinase 1;
GN   Name=TBK1; Synonyms=NAK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, INTERACTION WITH TANK AND TRAF2,
RP   AND MUTAGENESIS OF LYS-38.
RC   TISSUE=Spleen;
RX   PubMed=10581243; DOI=10.1093/emboj/18.23.6694;
RA   Pomerantz J.L., Baltimore D.;
RT   "NF-kB activation by a signaling complex containing TRAF2, TANK, and
RT   TBK1, a novel IKK-related kinase.";
RL   EMBO J. 18:6694-6704(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION IN PHOSPHORYLATION OF NFKBIA AND
RP   IKBKB, AND TISSUE SPECIFICITY.
RX   PubMed=10783893; DOI=10.1038/35008109;
RA   Tojima Y., Fujimoto A., Delhase M., Chen Y., Hatakeyama S.,
RA   Nakayama K., Kaneko Y., Nimura Y., Motoyama N., Ikeda K., Karin M.,
RA   Nakanishi M.;
RT   "NAK is an IkappaB kinase-activating kinase.";
RL   Nature 404:778-782(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ASP-388 AND
RP   GLN-570.
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION, MUTAGENESIS OF SER-172, AND PHOSPHORYLATION AT SER-172.
RX   PubMed=11839743; DOI=10.1074/jbc.M110474200;
RA   Kishore N., Huynh Q.K., Mathialagan S., Hall T., Rouw S., Creely D.,
RA   Lange G., Caroll J., Reitz B., Donnelly A., Boddupalli H., Combs R.G.,
RA   Kretzmer K., Tripp C.S.;
RT   "IKK-i and TBK-1 are enzymatically distinct from the homologous enzyme
RT   IKK-2: comparative analysis of recombinant human IKK-i, TBK-1, and
RT   IKK-2.";
RL   J. Biol. Chem. 277:13840-13847(2002).
RN   [7]
RP   INTERACTION WITH TIRAP AND TICAM1.
RX   PubMed=14530355; DOI=10.4049/jimmunol.171.8.4304;
RA   Sato S., Sugiyama M., Yamamoto M., Watanabe Y., Kawai T., Takeda K.,
RA   Akira S.;
RT   "Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF)
RT   associates with TNF receptor-associated factor 6 and TANK-binding
RT   kinase 1, and activates two distinct transcription factors, NF-kappa B
RT   and IFN-regulatory factor-3, in the Toll-like receptor signaling.";
RL   J. Immunol. 171:4304-4310(2003).
RN   [8]
RP   FUNCTION.
RX   PubMed=12692549; DOI=10.1038/ni921;
RA   Fitzgerald K.A., McWhirter S.M., Faia K.L., Rowe D.C., Latz E.,
RA   Golenbock D.T., Coyle A.J., Liao S.-M., Maniatis T.;
RT   "IKKepsilon and TBK1 are essential components of the IRF3 signaling
RT   pathway.";
RL   Nat. Immunol. 4:491-496(2003).
RN   [9]
RP   FUNCTION.
RX   PubMed=12702806; DOI=10.1126/science.1081315;
RA   Sharma S., tenOever B.R., Grandvaux N., Zhou G.-P., Lin R.,
RA   Hiscott J.;
RT   "Triggering the interferon antiviral response through an IKK-related
RT   pathway.";
RL   Science 300:1148-1151(2003).
RN   [10]
RP   INTERACTION WITH AZI2.
RX   PubMed=14560022; DOI=10.1128/MCB.23.21.7780-7793.2003;
RA   Fujita F., Taniguchi Y., Kato T., Narita Y., Furuya A., Ogawa T.,
RA   Sakurai H., Joh T., Itoh M., Delhase M., Karin M., Nakanishi M.;
RT   "Identification of NAP1, a regulatory subunit of IkappaB kinase-
RT   related kinases that potentiates NF-kappaB signaling.";
RL   Mol. Cell. Biol. 23:7780-7793(2003).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF IRF3.
RX   PubMed=14703513; DOI=10.1074/jbc.M310616200;
RA   Mori M., Yoneyama M., Ito T., Takahashi K., Inagaki F., Fujita T.;
RT   "Identification of Ser-386 of interferon regulatory factor 3 as
RT   critical target for inducible phosphorylation that determines
RT   activation.";
RL   J. Biol. Chem. 279:9698-9702(2004).
RN   [12]
RP   INTERACTION WITH TICAM1.
RX   PubMed=14739303; DOI=10.1074/jbc.M311629200;
RA   Han K.J., Su X., Xu L.-G., Bin L.H., Zhang J., Shu H.-B.;
RT   "Mechanisms of the TRIF-induced interferon-stimulated response element
RT   and NF-kappaB activation and apoptosis pathways.";
RL   J. Biol. Chem. 279:15652-15661(2004).
RN   [13]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15485837; DOI=10.1074/jbc.M411037200;
RA   Kuai J., Wooters J., Hall J.P., Rao V.R., Nickbarg E., Li B.,
RA   Chatterjee-Kishore M., Qiu Y., Lin L.-L.;
RT   "NAK is recruited to the TNFR1 complex in a TNFalpha-dependent manner
RT   and mediates the production of RANTES: identification of endogenous
RT   TNFR-interacting proteins by a proteomic approach.";
RL   J. Biol. Chem. 279:53266-53271(2004).
RN   [14]
RP   FUNCTION IN PHOSPHORYLATION OF RELA.
RX   PubMed=15489227; DOI=10.1074/jbc.M409825200;
RA   Buss H., Dorrie A., Schmitz M.L., Hoffmann E., Resch K., Kracht M.;
RT   "Constitutive and interleukin-1-inducible phosphorylation of p65
RT   NF-{kappa}B at serine 536 is mediated by multiple protein kinases
RT   including I{kappa}B kinase (IKK)-{alpha}, IKK{beta}, IKK{epsilon},
RT   TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an
RT   unknown kinase and couples p65 to TATA-binding protein-associated
RT   factor II31-mediated interleukin-8 transcription.";
RL   J. Biol. Chem. 279:55633-55643(2004).
RN   [15]
RP   FUNCTION IN PHOSPHORYLATION OF IRF7.
RX   PubMed=15367631; DOI=10.1128/JVI.78.19.10636-10649.2004;
RA   tenOever B.R., Sharma S., Zou W., Sun Q., Grandvaux N., Julkunen I.,
RA   Hemmi H., Yamamoto M., Akira S., Yeh W.C., Lin R., Hiscott J.;
RT   "Activation of TBK1 and IKKvarepsilon kinases by vesicular stomatitis
RT   virus infection and the role of viral ribonucleoprotein in the
RT   development of interferon antiviral immunity.";
RL   J. Virol. 78:10636-10649(2004).
RN   [16]
RP   INTERACTION WITH SIKE1; IRF3; TICAM1 AND DDX58.
RX   PubMed=16281057; DOI=10.1038/sj.emboj.7600863;
RA   Huang J., Liu T., Xu L.-G., Chen D., Zhai Z., Shu H.-B.;
RT   "SIKE is an IKK epsilon/TBK1-associated suppressor of TLR3- and virus-
RT   triggered IRF-3 activation pathways.";
RL   EMBO J. 24:4018-4028(2005).
RN   [17]
RP   INTERACTION WITH HCV NS3 (MICROBIAL INFECTION).
RX   PubMed=15841462; DOI=10.1002/hep.20666;
RA   Otsuka M., Kato N., Moriyama M., Taniguchi H., Wang Y., Dharel N.,
RA   Kawabe T., Omata M.;
RT   "Interaction between the HCV NS3 protein and the host TBK1 protein
RT   leads to inhibition of cellular antiviral responses.";
RL   Hepatology 41:1004-1012(2005).
RN   [18]
RP   FUNCTION, AND INTERACTION WITH BORNA DISEASE VIRUS P PROTEIN.
RX   PubMed=16155125; DOI=10.1073/pnas.0502883102;
RA   Unterstab G., Ludwig S., Anton A., Planz O., Dauber B., Krappmann D.,
RA   Heins G., Ehrhardt C., Wolff T.;
RT   "Viral targeting of the interferon-beta-inducing Traf family member-
RT   associated NF-kappa-B activator (TANK)-binding kinase-1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:13640-13645(2005).
RN   [19]
RP   INTERACTION WITH EXOC2.
RX   PubMed=17018283; DOI=10.1016/j.cell.2006.08.034;
RA   Chien Y., Kim S., Bumeister R., Loo Y.M., Kwon S.W., Johnson C.L.,
RA   Balakireva M.G., Romeo Y., Kopelovich L., Gale M. Jr., Yeaman C.,
RA   Camonis J.H., Zhao Y., White M.A.;
RT   "RalB GTPase-mediated activation of the IkappaB family kinase TBK1
RT   couples innate immune signaling to tumor cell survival.";
RL   Cell 127:157-170(2006).
RN   [20]
RP   DOMAIN.
RX   PubMed=17599067; DOI=10.1038/sj.emboj.7601773;
RA   Ikeda F., Hecker C.M., Rozenknop A., Nordmeier R.D., Rogov V.,
RA   Hofmann K., Akira S., Dotsch V., Dikic I.;
RT   "Involvement of the ubiquitin-like domain of TBK1/IKK-i kinases in
RT   regulation of IFN-inducible genes.";
RL   EMBO J. 26:3451-3462(2007).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION OF DDX3X.
RX   PubMed=18583960; DOI=10.1038/emboj.2008.126;
RA   Soulat D., Burckstummer T., Westermayer S., Goncalves A., Bauch A.,
RA   Stefanovic A., Hantschel O., Bennett K.L., Decker T.,
RA   Superti-Furga G.;
RT   "The DEAD-box helicase DDX3X is a critical component of the TANK-
RT   binding kinase 1-dependent innate immune response.";
RL   EMBO J. 27:2135-2146(2008).
RN   [22]
RP   INTERACTION WITH CYLD.
RX   PubMed=18636086; DOI=10.1038/embor.2008.136;
RA   Friedman C.S., O'Donnell M.A., Legarda-Addison D., Ng A.,
RA   Cardenas W.B., Yount J.S., Moran T.M., Basler C.F., Komuro A.,
RA   Horvath C.M., Xavier R., Ting A.T.;
RT   "The tumour suppressor CYLD is a negative regulator of RIG-I-mediated
RT   antiviral response.";
RL   EMBO Rep. 9:930-936(2008).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [24]
RP   INTERACTION WITH SRC.
RX   PubMed=19419966; DOI=10.1074/jbc.M808233200;
RA   Johnsen I.B., Nguyen T.T., Bergstroem B., Fitzgerald K.A.,
RA   Anthonsen M.W.;
RT   "The tyrosine kinase c-Src enhances RIG-I (retinoic acid-inducible
RT   gene I)-elicited antiviral signaling.";
RL   J. Biol. Chem. 284:19122-19131(2009).
RN   [25]
RP   INTERACTION WITH EBOLAVIRUS PROTEIN VP35, AND AUTOPHOSPHORYLATION.
RX   PubMed=19153231; DOI=10.1128/JVI.01875-08;
RA   Prins K.C., Cardenas W.B., Basler C.F.;
RT   "Ebola virus protein VP35 impairs the function of interferon
RT   regulatory factor-activating kinases IKKepsilon and TBK-1.";
RL   J. Virol. 83:3069-3077(2009).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [27]
RP   UBIQUITINATION BY NRDP1.
RX   PubMed=19483718; DOI=10.1038/ni.1742;
RA   Wang C., Chen T., Zhang J., Yang M., Li N., Xu X., Cao X.;
RT   "The E3 ubiquitin ligase Nrdp1 'preferentially' promotes TLR-mediated
RT   production of type I interferon.";
RL   Nat. Immunol. 10:744-752(2009).
RN   [28]
RP   INTERACTION WITH TMEM173/MITA.
RX   PubMed=19416887; DOI=10.1073/pnas.0900818106;
RA   Li Y., Li C., Xue P., Zhong B., Mao A.P., Ran Y., Chen H., Wang Y.Y.,
RA   Yang F., Shu H.B.;
RT   "ISG56 is a negative-feedback regulator of virus-triggered signaling
RT   and cellular antiviral response.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:7945-7950(2009).
RN   [29]
RP   AUTOPHOSPHORYLATION, SUBUNIT, AND INTERACTION WITH GSK3B.
RX   PubMed=21145761; DOI=10.1016/j.immuni.2010.11.021;
RA   Lei C.Q., Zhong B., Zhang Y., Zhang J., Wang S., Shu H.B.;
RT   "Glycogen synthase kinase 3beta regulates IRF3 transcription factor-
RT   mediated antiviral response via activation of the kinase TBK1.";
RL   Immunity 33:878-889(2010).
RN   [30]
RP   INTERACTION WITH OPTN AND TRAF3.
RX   PubMed=20174559; DOI=10.1371/journal.ppat.1000778;
RA   Mankouri J., Fragkoudis R., Richards K.H., Wetherill L.F., Harris M.,
RA   Kohl A., Elliott R.M., Macdonald A.;
RT   "Optineurin negatively regulates the induction of IFNbeta in response
RT   to RNA virus infection.";
RL   PLoS Pathog. 6:E1000778-E1000778(2010).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [32]
RP   INVOLVEMENT IN GLC1P, TISSUE SPECIFICITY, AND VARIANTS PHE-151;
RP   ILE-306 AND ALA-464.
RX   PubMed=21447600; DOI=10.1093/hmg/ddr123;
RA   Fingert J.H., Robin A.L., Stone J.L., Roos B.R., Davis L.K.,
RA   Scheetz T.E., Bennett S.R., Wassink T.H., Kwon Y.H., Alward W.L.,
RA   Mullins R.F., Sheffield V.C., Stone E.M.;
RT   "Copy number variations on chromosome 12q14 in patients with normal
RT   tension glaucoma.";
RL   Hum. Mol. Genet. 20:2482-2494(2011).
RN   [33]
RP   UBIQUITINATION BY MIB1.
RX   PubMed=21903422; DOI=10.1016/j.immuni.2011.06.014;
RA   Li S., Wang L., Berman M., Kong Y.Y., Dorf M.E.;
RT   "Mapping a dynamic innate immunity protein interaction network
RT   regulating type I interferon production.";
RL   Immunity 35:426-440(2011).
RN   [34]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH IFIT3 AND MAVS.
RX   PubMed=21813773; DOI=10.4049/jimmunol.1100963;
RA   Liu X.Y., Chen W., Wei B., Shan Y.F., Wang C.;
RT   "IFN-induced TPR protein IFIT3 potentiates antiviral signaling by
RT   bridging MAVS and TBK1.";
RL   J. Immunol. 187:2559-2568(2011).
RN   [35]
RP   FUNCTION IN PHOSPHORYLATION OF VPS37C.
RX   PubMed=21270402; DOI=10.4049/jimmunol.1000262;
RA   Da Q., Yang X., Xu Y., Gao G., Cheng G., Tang H.;
RT   "TANK-binding kinase 1 attenuates PTAP-dependent retroviral budding
RT   through targeting endosomal sorting complex required for transport-
RT   I.";
RL   J. Immunol. 186:3023-3030(2011).
RN   [36]
RP   FUNCTION, INTERACTION WITH AZI2; TANK AND TBKBP1, AND MUTAGENESIS OF
RP   ASP-135; MET-690; LEU-693; LYS-694; LEU-704; ASN-708 AND LEU-711.
RX   PubMed=21931631; DOI=10.1371/journal.pone.0023971;
RA   Goncalves A., Burckstummer T., Dixit E., Scheicher R., Gorna M.W.,
RA   Karayel E., Sugar C., Stukalov A., Berg T., Kralovics R.,
RA   Planyavsky M., Bennett K.L., Colinge J., Superti-Furga G.;
RT   "Functional dissection of the TBK1 molecular network.";
RL   PLoS ONE 6:E23971-E23971(2011).
RN   [37]
RP   FUNCTION IN PHOSPHORYLATION OF AKT1.
RX   PubMed=21464307; DOI=10.1073/pnas.1016132108;
RA   Xie X., Zhang D., Zhao B., Lu M.K., You M., Condorelli G., Wang C.Y.,
RA   Guan K.L.;
RT   "IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by
RT   direct phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:6474-6479(2011).
RN   [38]
RP   FUNCTION IN PHOSPHORYLATION OF OPTN.
RX   PubMed=21617041; DOI=10.1126/science.1205405;
RA   Wild P., Farhan H., McEwan D.G., Wagner S., Rogov V.V., Brady N.R.,
RA   Richter B., Korac J., Waidmann O., Choudhary C., Dotsch V., Bumann D.,
RA   Dikic I.;
RT   "Phosphorylation of the autophagy receptor optineurin restricts
RT   Salmonella growth.";
RL   Science 333:228-233(2011).
RN   [39]
RP   REVIEW ON FUNCTION, AND DOMAIN.
RX   PubMed=21042276; DOI=10.1038/onc.2010.493;
RA   Shen R.R., Hahn W.C.;
RT   "Emerging roles for the non-canonical IKKs in cancer.";
RL   Oncogene 30:631-641(2011).
RN   [40]
RP   FUNCTION, AND PHOSPHORYLATION BY IKBKB/IKKB.
RX   PubMed=21138416; DOI=10.1042/BJ20101701;
RA   Clark K., Peggie M., Plater L., Sorcek R.J., Young E.R., Madwed J.B.,
RA   Hough J., McIver E.G., Cohen P.;
RT   "Novel cross-talk within the IKK family controls innate immunity.";
RL   Biochem. J. 434:93-104(2011).
RN   [41]
RP   DEPHOSPHORYLATION AT SER-172.
RX   PubMed=22750291; DOI=10.1016/j.cellsig.2012.06.017;
RA   Zhao Y., Liang L., Fan Y., Sun S., An L., Shi Z., Cheng J., Jia W.,
RA   Sun W., Mori-Akiyama Y., Zhang H., Fu S., Yang J.;
RT   "PPM1B negatively regulates antiviral response via dephosphorylating
RT   TBK1.";
RL   Cell. Signal. 24:2197-2204(2012).
RN   [42]
RP   INVOLVEMENT IN GLC1P.
RX   PubMed=22306015; DOI=10.1016/j.exer.2011.12.021;
RA   Kawase K., Allingham R.R., Meguro A., Mizuki N., Roos B.,
RA   Solivan-Timpe F.M., Robin A.L., Ritch R., Fingert J.H.;
RT   "Confirmation of TBK1 duplication in normal tension glaucoma.";
RL   Exp. Eye Res. 96:178-180(2012).
RN   [43]
RP   UBIQUITINATION BY TRAIP.
RX   PubMed=22945920; DOI=10.1084/jem.20120024;
RA   Zhang M., Wang L., Zhao X., Zhao K., Meng H., Zhao W., Gao C.;
RT   "TRAF-interacting protein (TRIP) negatively regulates IFN-beta
RT   production and antiviral response by promoting proteasomal degradation
RT   of TANK-binding kinase 1.";
RL   J. Exp. Med. 209:1703-1711(2012).
RN   [44]
RP   UBIQUITINATION AT LYS-670 BY DTX4.
RX   PubMed=22388039; DOI=10.1038/ni.2239;
RA   Cui J., Li Y., Zhu L., Liu D., Songyang Z., Wang H.Y., Wang R.F.;
RT   "NLRP4 negatively regulates type I interferon signaling by targeting
RT   the kinase TBK1 for degradation via the ubiquitin ligase DTX4.";
RL   Nat. Immunol. 13:387-395(2012).
RN   [45]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-716, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [46]
RP   INVOLVEMENT IN FTDALS4, AND VARIANTS FTDALS4 ILE-306; GLU-401 AND
RP   LYS-696.
RX   PubMed=25943890; DOI=10.1007/s00401-015-1436-x;
RA   Pottier C., Bieniek K.F., Finch N., van de Vorst M., Baker M.,
RA   Perkersen R., Brown P., Ravenscroft T., van Blitterswijk M.,
RA   Nicholson A.M., DeTure M., Knopman D.S., Josephs K.A., Parisi J.E.,
RA   Petersen R.C., Boylan K.B., Boeve B.F., Graff-Radford N.R.,
RA   Veltman J.A., Gilissen C., Murray M.E., Dickson D.W., Rademakers R.;
RT   "Whole-genome sequencing reveals important role for TBK1 and OPTN
RT   mutations in frontotemporal lobar degeneration without motor neuron
RT   disease.";
RL   Acta Neuropathol. 130:77-92(2015).
RN   [47]
RP   INTERACTION WITH TICAM1.
RX   PubMed=25736436; DOI=10.15252/embr.201439637;
RA   Hu Y.H., Zhang Y., Jiang L.Q., Wang S., Lei C.Q., Sun M.S., Shu H.B.,
RA   Liu Y.;
RT   "WDFY1 mediates TLR3/4 signaling by recruiting TRIF.";
RL   EMBO Rep. 16:447-455(2015).
RN   [48]
RP   INVOLVEMENT IN FTDALS4, VARIANTS FTDALS4 HIS-47; CYS-105; THR-305;
RP   GLN-308; GLN-357; ARG-559; VAL-571; VAL-598; GLU-643 DEL AND LYS-696,
RP   AND CHARACTERIZATION OF VARIANTS FTDALS4 HIS-47; GLN-308; GLN-357;
RP   ARG-559 AND LYS-696.
RX   PubMed=25803835; DOI=10.1038/nn.4000;
RA   Freischmidt A., Wieland T., Richter B., Ruf W., Schaeffer V.,
RA   Mueller K., Marroquin N., Nordin F., Huebers A., Weydt P., Pinto S.,
RA   Press R., Millecamps S., Molko N., Bernard E., Desnuelle C.,
RA   Soriani M.H., Dorst J., Graf E., Nordstroem U., Feiler M.S., Putz S.,
RA   Boeckers T.M., Meyer T., Winkler A.S., Winkelman J., de Carvalho M.,
RA   Thal D.R., Otto M., Braennstroem T., Volk A.E., Kursula P.,
RA   Danzer K.M., Lichtner P., Dikic I., Meitinger T., Ludolph A.C.,
RA   Strom T.M., Andersen P.M., Weishaupt J.H.;
RT   "Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal
RT   dementia.";
RL   Nat. Neurosci. 18:631-636(2015).
RN   [49]
RP   FUNCTION.
RX   PubMed=27103069; DOI=10.15252/embj.201593350;
RA   Sellier C., Campanari M.L., Julie Corbier C., Gaucherot A.,
RA   Kolb-Cheynel I., Oulad-Abdelghani M., Ruffenach F., Page A., Ciura S.,
RA   Kabashi E., Charlet-Berguerand N.;
RT   "Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin-2
RT   to induce motor neuron dysfunction and cell death.";
RL   EMBO J. 35:1276-1297(2016).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 1-657 IN COMPLEX WITH
RP   INHIBITORS, FUNCTION, ACTIVE SITE, HOMODIMER, UBIQUITINATION AT LYS-30
RP   AND LYS-401, AND MUTAGENESIS OF LYS-30; ASP-33; LYS-38; ASP-135;
RP   GLU-355; ARG-357; LYS-401; ARG-547; TYR-577; GLU-580; ILE-582 AND
RP   LYS-589.
RX   PubMed=23453971; DOI=10.1016/j.celrep.2013.01.034;
RA   Larabi A., Devos J.M., Ng S.L., Nanao M.H., Round A., Maniatis T.,
RA   Panne D.;
RT   "Crystal structure and mechanism of activation of TANK-binding kinase
RT   1.";
RL   Cell Rep. 3:734-746(2013).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (2.61 ANGSTROMS) OF 1-657 IN COMPLEX WITH
RP   INHIBITORS, FUNCTION, ACTIVE SITE, AUTOPHOSPHORYLATION, HOMODIMER,
RP   INTERACTION WITH AZI2, AND MUTAGENESIS OF LYS-38; ASP-135; SER-172;
RP   LEU-316; TYR-325; GLU-355; GLU-448; HIS-459; ILE-466 AND PHE-470.
RX   PubMed=23453972; DOI=10.1016/j.celrep.2013.01.033;
RA   Tu D., Zhu Z., Zhou A.Y., Yun C.H., Lee K.E., Toms A.V., Li Y.,
RA   Dunn G.P., Chan E., Thai T., Yang S., Ficarro S.B., Marto J.A.,
RA   Jeon H., Hahn W.C., Barbie D.A., Eck M.J.;
RT   "Structure and ubiquitination-dependent activation of TANK-binding
RT   kinase 1.";
RL   Cell Rep. 3:747-758(2013).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 1-657 IN COMPLEX WITH
RP   INHIBITORS, FUNCTION, AND PHOSPHORYLATION AT SER-172.
RX   PubMed=23746807; DOI=10.1016/j.str.2013.04.025;
RA   Shu C., Sankaran B., Chaton C.T., Herr A.B., Mishra A., Peng J.,
RA   Li P.;
RT   "Structural insights into the functions of TBK1 in innate
RT   antimicrobial immunity.";
RL   Structure 21:1137-1148(2013).
RN   [53]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLN-271; GLU-291; HIS-296; ARG-410 AND
RP   ALA-464.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine kinase that plays an essential role in
CC       regulating inflammatory responses to foreign agents. Following
CC       activation of toll-like receptors by viral or bacterial
CC       components, associates with TRAF3 and TANK and phosphorylates
CC       interferon regulatory factors (IRFs) IRF3 and IRF7 as well as
CC       DDX3X. This activity allows subsequent homodimerization and
CC       nuclear translocation of the IRFs leading to transcriptional
CC       activation of pro-inflammatory and antiviral genes including IFNA
CC       and IFNB. In order to establish such an antiviral state, TBK1 form
CC       several different complexes whose composition depends on the type
CC       of cell and cellular stimuli. Thus, several scaffolding molecules
CC       including FADD, TRADD, MAVS, AZI2, TANK or TBKBP1/SINTBAD can be
CC       recruited to the TBK1-containing-complexes. Under particular
CC       conditions, functions as a NF-kappa-B effector by phosphorylating
CC       NF-kappa-B inhibitor alpha/NFKBIA, IKBKB or RELA to translocate
CC       NF-Kappa-B to the nucleus. Restricts bacterial proliferation by
CC       phosphorylating the autophagy receptor OPTN/Optineurin on 'Ser-
CC       177', thus enhancing LC3 binding affinity and antibacterial
CC       autophagy (PubMed:21617041). Phosphorylates SMCR8 component of the
CC       C9orf72-SMCR8 complex, promoting autophagosome maturation
CC       (PubMed:27103069). Phosphorylates and activates AKT1
CC       (PubMed:21464307). Seems to play a role in energy balance
CC       regulation by sustaining a state of chronic, low-grade
CC       inflammation in obesity, wich leads to a negative impact on
CC       insulin sensitivity. Attenuates retroviral budding by
CC       phosphorylating the endosomal sorting complex required for
CC       transport-I (ESCRT-I) subunit VPS37C (PubMed:21270402).
CC       Phosphorylates Borna disease virus (BDV) P protein
CC       (PubMed:16155125). {ECO:0000269|PubMed:10581243,
CC       ECO:0000269|PubMed:10783893, ECO:0000269|PubMed:11839743,
CC       ECO:0000269|PubMed:12692549, ECO:0000269|PubMed:12702806,
CC       ECO:0000269|PubMed:14703513, ECO:0000269|PubMed:15367631,
CC       ECO:0000269|PubMed:15485837, ECO:0000269|PubMed:15489227,
CC       ECO:0000269|PubMed:16155125, ECO:0000269|PubMed:18583960,
CC       ECO:0000269|PubMed:21138416, ECO:0000269|PubMed:21270402,
CC       ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:21617041,
CC       ECO:0000269|PubMed:21931631, ECO:0000269|PubMed:23453971,
CC       ECO:0000269|PubMed:23453972, ECO:0000269|PubMed:23746807,
CC       ECO:0000269|PubMed:27103069}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- SUBUNIT: Homodimer. Interacts with DDX3X, TIRAP and TRAF2. Part of
CC       a ternary complex consisting of TANK, TRAF2 and TBK1. Interacts
CC       with AZI2, TANK and TBKBP1; these interactions are mutually
CC       exclusive and mediate TBK1 activation. Interacts with GSK3B; this
CC       interaction promotes TBK1 self-association and
CC       autophosphorylation. Interacts with SIKE1; SIKE1 is associated
CC       with TBK1 under physiological condition and dissociated from TBK1
CC       upon viral infection or TLR3 stimulation. Interacts with IRF3 and
CC       DDX58/RIG-I. Interacts with CYLD. Interacts with OPTN and TRAF3.
CC       Interacts with SRC. Interacts with the exocyst complex subunit
CC       SEC5/EXOC2; this interaction is sufficient to trigger TBK1
CC       activity. Interacts with TMEM173/MITA. Interacts with IFIT3 (via
CC       N-terminus). Interacts with MAVS only in the presence of IFIT3.
CC       Interacts with TICAM1 and this interaction is enhanced in the
CC       presence of WDFY1 (PubMed:25736436). {ECO:0000269|PubMed:10581243,
CC       ECO:0000269|PubMed:14530355, ECO:0000269|PubMed:14560022,
CC       ECO:0000269|PubMed:14739303, ECO:0000269|PubMed:16155125,
CC       ECO:0000269|PubMed:16281057, ECO:0000269|PubMed:17018283,
CC       ECO:0000269|PubMed:18636086, ECO:0000269|PubMed:19153231,
CC       ECO:0000269|PubMed:19416887, ECO:0000269|PubMed:19419966,
CC       ECO:0000269|PubMed:20174559, ECO:0000269|PubMed:21145761,
CC       ECO:0000269|PubMed:21813773, ECO:0000269|PubMed:21931631,
CC       ECO:0000269|PubMed:23453971, ECO:0000269|PubMed:23453972,
CC       ECO:0000269|PubMed:23746807, ECO:0000269|PubMed:25736436}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HCV NS3; this
CC       interaction leads to inhibition of cellular antiviral response by
CC       blocking necessary interactions between the TBK1 and its
CC       substrates IRF3 and IRF7. {ECO:0000269|PubMed:15841462}.
CC   -!- INTERACTION:
CC       I0DF37:- (xeno); NbExp=3; IntAct=EBI-356402, EBI-9543922;
CC       I6W9F2:- (xeno); NbExp=6; IntAct=EBI-356402, EBI-9518472;
CC       K7Y1A2:- (xeno); NbExp=2; IntAct=EBI-356402, EBI-8788634;
CC       P27958:- (xeno); NbExp=4; IntAct=EBI-356402, EBI-3649474;
CC       Q9UKV8:AGO2; NbExp=2; IntAct=EBI-356402, EBI-528269;
CC       Q7Z3C6:ATG9A; NbExp=2; IntAct=EBI-356402, EBI-727146;
CC       Q9H6S1:AZI2; NbExp=3; IntAct=EBI-356402, EBI-359973;
CC       Q13137:CALCOCO2; NbExp=5; IntAct=EBI-356402, EBI-739580;
CC       Q6DT37:CDC42BPG; NbExp=2; IntAct=EBI-356402, EBI-689124;
CC       Q62167:Ddx3x (xeno); NbExp=8; IntAct=EBI-356402, EBI-773173;
CC       O41932:GAMMAHV.ORF11 (xeno); NbExp=4; IntAct=EBI-356402, EBI-9544132;
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-356402, EBI-352572;
CC       Q14164:IKBKE; NbExp=2; IntAct=EBI-356402, EBI-307369;
CC       Q9Y6K9:IKBKG; NbExp=2; IntAct=EBI-356402, EBI-81279;
CC       Q14653:IRF3; NbExp=9; IntAct=EBI-356402, EBI-2650369;
CC       Q92985:IRF7; NbExp=2; IntAct=EBI-356402, EBI-968267;
CC       Q7Z434:MAVS; NbExp=2; IntAct=EBI-356402, EBI-995373;
CC       Q86YT6:MIB1; NbExp=2; IntAct=EBI-356402, EBI-2129148;
CC       Q96AX9:MIB2; NbExp=2; IntAct=EBI-356402, EBI-2130249;
CC       Q9NVV4:MTPAP; NbExp=2; IntAct=EBI-356402, EBI-2556166;
CC       Q96CV9:OPTN; NbExp=12; IntAct=EBI-356402, EBI-748974;
CC       O14730:RIOK3; NbExp=3; IntAct=EBI-356402, EBI-1047061;
CC       P42226:STAT6; NbExp=7; IntAct=EBI-356402, EBI-1186478;
CC       Q92844:TANK; NbExp=7; IntAct=EBI-356402, EBI-356349;
CC       A7MCY6:TBKBP1; NbExp=8; IntAct=EBI-356402, EBI-359969;
CC       Q86WV6:TMEM173; NbExp=3; IntAct=EBI-356402, EBI-2800345;
CC       Q12933:TRAF2; NbExp=3; IntAct=EBI-356402, EBI-355744;
CC       P40222:TXLNA; NbExp=4; IntAct=EBI-356402, EBI-359793;
CC       Q8BHN1:Txlng (xeno); NbExp=2; IntAct=EBI-356402, EBI-6116854;
CC       Q05127:VP35 (xeno); NbExp=2; IntAct=EBI-356402, EBI-6148294;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15485837,
CC       ECO:0000269|PubMed:21813773}. Note=Upon mitogen stimulation or
CC       triggering of the immune system, TBK1 is recruited to the exocyst
CC       by EXOC2.
CC   -!- TISSUE SPECIFICITY: Ubiquitous with higher expression in testis.
CC       Expressed in the ganglion cells, nerve fiber layer and
CC       microvasculature of the retina. {ECO:0000269|PubMed:10783893,
CC       ECO:0000269|PubMed:21447600}.
CC   -!- DOMAIN: Comprises A N-terminal kinase domain, a ubiquitin-like
CC       domain and a C-terminal coiled-coil region mediating
CC       homodimerization. {ECO:0000269|PubMed:17599067,
CC       ECO:0000269|PubMed:21042276}.
CC   -!- PTM: Autophosphorylation at Ser-172 activates the kinase, and is
CC       an essential step for virus-triggered signaling. Phosphorylated by
CC       IKBKB/IKKB at Ser-172. Phosphorylation requires homodimerization
CC       and ubiquitination at Lys-30 and Lys-401. Dephosphorylated at Ser-
CC       172 by PPM1B and this negatively regulates its role in mediating
CC       antiviral response. {ECO:0000269|PubMed:11839743,
CC       ECO:0000269|PubMed:21138416, ECO:0000269|PubMed:23453971,
CC       ECO:0000269|PubMed:23746807}.
CC   -!- PTM: 'Lys-63'-linked polyubiquitination by MIB1 after RNA virus
CC       infection, or by NRDP1 after LPS stimulation at Lys-30 and Lys-
CC       401, participates in kinase activation. 'Lys-48'-linked
CC       polyubiquitination at Lys-670 by DTX4 leads to proteasomal
CC       degradation. 'Lys-48'-linked polyubiquitination by TRAIP also
CC       leads to proteasomal degradation. {ECO:0000269|PubMed:22388039,
CC       ECO:0000269|PubMed:23453971}.
CC   -!- DISEASE: Glaucoma 1, open angle, P (GLC1P) [MIM:177700]: A form of
CC       primary open angle glaucoma (POAG). POAG is characterized by a
CC       specific pattern of optic nerve and visual field defects. The
CC       angle of the anterior chamber of the eye is open, and usually the
CC       intraocular pressure is increased. However, glaucoma can occur at
CC       any intraocular pressure. The disease is generally asymptomatic
CC       until the late stages, by which time significant and irreversible
CC       optic nerve damage has already taken place. GLC1P is characterized
CC       by early onset, thin central corneas and low intraocular pressure.
CC       {ECO:0000269|PubMed:21447600, ECO:0000269|PubMed:22306015}.
CC       Note=The disease may be caused by mutations affecting the gene
CC       represented in this entry. A copy number variation on chromosome
CC       12q14 consisting of a 300 kb duplication that includes TBK1, XPOT,
CC       RASSF3 and GNS has been found in individuals affected by glaucoma.
CC       TBK1 is the most likely candidate for the disorder
CC       (PubMed:21447600). {ECO:0000269|PubMed:21447600}.
CC   -!- DISEASE: Frontotemporal dementia and/or amyotrophic lateral
CC       sclerosis 4 (FTDALS4) [MIM:616439]: A neurodegenerative disorder
CC       characterized by frontotemporal dementia and/or amyotrophic
CC       lateral sclerosis in affected individuals. There is high
CC       intrafamilial variation. Frontotemporal dementia is characterized
CC       by frontal and temporal lobe atrophy associated with neuronal
CC       loss, gliosis, and dementia. Patients exhibit progressive changes
CC       in social, behavioral, and/or language function. Amyotrophic
CC       lateral sclerosis is characterized by the death of motor neurons
CC       in the brain, brainstem, and spinal cord, resulting in fatal
CC       paralysis. {ECO:0000269|PubMed:25803835,
CC       ECO:0000269|PubMed:25943890}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: In cancer cells, pathological TBK1 activation
CC       promotes oncogenic transformation by suppressing programmed cell
CC       death. Mechanistically, the RALB-SEC5/EXOC2-TBK1 signaling cascade
CC       seems to participate in both innate immune signaling and cell
CC       transformation. Additionally, TBK1 supports oncogenesis by
CC       directly phosphorylating and activating AKT1 at the exocyst
CC       (PubMed:21042276). {ECO:0000305|PubMed:21042276}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family. I-kappa-B kinase subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA92129.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF191838; AAF05989.1; -; mRNA.
DR   EMBL; AF174536; AAF69106.1; -; mRNA.
DR   EMBL; AK002192; BAA92129.1; ALT_INIT; mRNA.
DR   EMBL; AK291039; BAF83728.1; -; mRNA.
DR   EMBL; CH471054; EAW97133.1; -; Genomic_DNA.
DR   EMBL; BC034950; AAH34950.1; -; mRNA.
DR   CCDS; CCDS8968.1; -.
DR   RefSeq; NP_037386.1; NM_013254.3.
DR   RefSeq; XP_005268866.1; XM_005268809.1.
DR   RefSeq; XP_005268867.1; XM_005268810.1.
DR   UniGene; Hs.505874; -.
DR   PDB; 4EFO; X-ray; 1.77 A; A/B=302-383.
DR   PDB; 4EUT; X-ray; 2.60 A; A/B=2-385.
DR   PDB; 4EUU; X-ray; 1.80 A; A/B=2-308.
DR   PDB; 4IM0; X-ray; 2.40 A; A=1-657.
DR   PDB; 4IM2; X-ray; 2.50 A; A=1-657.
DR   PDB; 4IM3; X-ray; 3.34 A; A=1-657.
DR   PDB; 4IW0; X-ray; 4.00 A; A=2-657.
DR   PDB; 4IWO; X-ray; 2.61 A; A=2-657.
DR   PDB; 4IWP; X-ray; 3.06 A; A=2-657.
DR   PDB; 4IWQ; X-ray; 3.00 A; A=2-657.
DR   PDB; 5EOA; X-ray; 2.50 A; C/D=677-729.
DR   PDB; 5EOF; X-ray; 2.05 A; C/D=677-729.
DR   PDB; 5EP6; X-ray; 1.45 A; B/D=677-729.
DR   PDBsum; 4EFO; -.
DR   PDBsum; 4EUT; -.
DR   PDBsum; 4EUU; -.
DR   PDBsum; 4IM0; -.
DR   PDBsum; 4IM2; -.
DR   PDBsum; 4IM3; -.
DR   PDBsum; 4IW0; -.
DR   PDBsum; 4IWO; -.
DR   PDBsum; 4IWP; -.
DR   PDBsum; 4IWQ; -.
DR   PDBsum; 5EOA; -.
DR   PDBsum; 5EOF; -.
DR   PDBsum; 5EP6; -.
DR   ProteinModelPortal; Q9UHD2; -.
DR   SMR; Q9UHD2; -.
DR   BioGrid; 118878; 118.
DR   DIP; DIP-27529N; -.
DR   IntAct; Q9UHD2; 78.
DR   MINT; MINT-1131333; -.
DR   STRING; 9606.ENSP00000329967; -.
DR   BindingDB; Q9UHD2; -.
DR   ChEMBL; CHEMBL5408; -.
DR   GuidetoPHARMACOLOGY; 2237; -.
DR   iPTMnet; Q9UHD2; -.
DR   PhosphoSitePlus; Q9UHD2; -.
DR   BioMuta; TBK1; -.
DR   DMDM; 74761953; -.
DR   EPD; Q9UHD2; -.
DR   MaxQB; Q9UHD2; -.
DR   PaxDb; Q9UHD2; -.
DR   PeptideAtlas; Q9UHD2; -.
DR   PRIDE; Q9UHD2; -.
DR   DNASU; 29110; -.
DR   Ensembl; ENST00000331710; ENSP00000329967; ENSG00000183735.
DR   GeneID; 29110; -.
DR   KEGG; hsa:29110; -.
DR   UCSC; uc001ssc.3; human.
DR   CTD; 29110; -.
DR   DisGeNET; 29110; -.
DR   GeneCards; TBK1; -.
DR   HGNC; HGNC:11584; TBK1.
DR   HPA; HPA045797; -.
DR   HPA; HPA060211; -.
DR   MalaCards; TBK1; -.
DR   MIM; 177700; phenotype.
DR   MIM; 604834; gene.
DR   MIM; 616439; phenotype.
DR   neXtProt; NX_Q9UHD2; -.
DR   OpenTargets; ENSG00000183735; -.
DR   Orphanet; 1930; Herpetic encephalitis.
DR   PharmGKB; PA36348; -.
DR   eggNOG; KOG4250; Eukaryota.
DR   eggNOG; ENOG410XRMU; LUCA.
DR   GeneTree; ENSGT00820000127009; -.
DR   HOGENOM; HOG000220867; -.
DR   HOVERGEN; HBG008494; -.
DR   InParanoid; Q9UHD2; -.
DR   KO; K05410; -.
DR   OMA; FRGRHKK; -.
DR   OrthoDB; EOG091G0354; -.
DR   PhylomeDB; Q9UHD2; -.
DR   TreeFam; TF324269; -.
DR   Reactome; R-HSA-1606341; IRF3 mediated activation of type 1 IFN.
DR   Reactome; R-HSA-3134975; Regulation of innate immune responses to cytosolic DNA.
DR   Reactome; R-HSA-3249367; STAT6-mediated induction of chemokines.
DR   Reactome; R-HSA-3270619; IRF3-mediated induction of type I IFN.
DR   Reactome; R-HSA-918233; TRAF3-dependent IRF activation pathway.
DR   Reactome; R-HSA-933541; TRAF6 mediated IRF7 activation.
DR   Reactome; R-HSA-936440; Negative regulators of RIG-I/MDA5 signaling.
DR   Reactome; R-HSA-936964; Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon.
DR   SABIO-RK; Q9UHD2; -.
DR   SignaLink; Q9UHD2; -.
DR   SIGNOR; Q9UHD2; -.
DR   GeneWiki; TANK-binding_kinase_1; -.
DR   GenomeRNAi; 29110; -.
DR   PRO; PR:Q9UHD2; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000183735; -.
DR   CleanEx; HS_TBK1; -.
DR   ExpressionAtlas; Q9UHD2; baseline and differential.
DR   Genevisible; Q9UHD2; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0010008; C:endosome membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003676; F:nucleic acid binding; IEA:Ensembl.
DR   GO; GO:0051219; F:phosphoprotein binding; IPI:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; TAS:Reactome.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; IEA:Ensembl.
DR   GO; GO:0051607; P:defense response to virus; IEA:UniProtKB-KW.
DR   GO; GO:0044565; P:dendritic cell proliferation; IEA:Ensembl.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; TAS:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; TAS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; TAS:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0032480; P:negative regulation of type I interferon production; TAS:Reactome.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:HGNC.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IEP:UniProtKB.
DR   GO; GO:0032727; P:positive regulation of interferon-alpha production; IDA:BHF-UCL.
DR   GO; GO:0045359; P:positive regulation of interferon-beta biosynthetic process; IEA:Ensembl.
DR   GO; GO:0032728; P:positive regulation of interferon-beta production; IDA:BHF-UCL.
DR   GO; GO:0016239; P:positive regulation of macroautophagy; IDA:HGNC.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; NAS:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0032481; P:positive regulation of type I interferon production; TAS:Reactome.
DR   GO; GO:1904417; P:positive regulation of xenophagy; IEA:Ensembl.
DR   GO; GO:1901214; P:regulation of neuron death; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0032479; P:regulation of type I interferon production; TAS:Reactome.
DR   GO; GO:0009615; P:response to virus; TAS:UniProtKB.
DR   GO; GO:0035666; P:TRIF-dependent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0032606; P:type I interferon production; TAS:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Amyotrophic lateral sclerosis; Antiviral defense;
KW   ATP-binding; Coiled coil; Complete proteome; Cytoplasm;
KW   Disease mutation; Glaucoma; Host-virus interaction; Immunity;
KW   Innate immunity; Isopeptide bond; Kinase; Neurodegeneration;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   CHAIN         1    729       Serine/threonine-protein kinase TBK1.
FT                                /FTId=PRO_0000086743.
FT   DOMAIN        9    310       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      309    385       Ubiquitin-like.
FT   NP_BIND      15     23       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      621    629       Interaction with AZI2, TANK and TBKBP1.
FT                                {ECO:0000269|PubMed:21931631}.
FT   COILED      407    657
FT   COILED      658    713       {ECO:0000255}.
FT   ACT_SITE    135    135       Proton acceptor.
FT                                {ECO:0000305|PubMed:23453971,
FT                                ECO:0000305|PubMed:23453972}.
FT   BINDING      38     38       ATP. {ECO:0000305}.
FT   MOD_RES     172    172       Phosphoserine; by autocatalysis and IKKB.
FT                                {ECO:0000269|PubMed:11839743,
FT                                ECO:0000269|PubMed:23746807}.
FT   MOD_RES     716    716       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   CROSSLNK     30     30       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:23453971}.
FT   CROSSLNK    401    401       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:23453971}.
FT   CROSSLNK    670    670       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:22388039}.
FT   VARIANT      47     47       R -> H (in FTDALS4; loss of kinase
FT                                activity). {ECO:0000269|PubMed:25803835}.
FT                                /FTId=VAR_073938.
FT   VARIANT     105    105       Y -> C (in FTDALS4).
FT                                {ECO:0000269|PubMed:25803835}.
FT                                /FTId=VAR_073939.
FT   VARIANT     151    151       S -> F (in dbSNP:rs55824172).
FT                                {ECO:0000269|PubMed:21447600}.
FT                                /FTId=VAR_069754.
FT   VARIANT     271    271       R -> Q (in dbSNP:rs56196591).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041208.
FT   VARIANT     291    291       K -> E (in dbSNP:rs34774243).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041209.
FT   VARIANT     296    296       D -> H (in a breast pleomorphic lobular
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041210.
FT   VARIANT     305    305       I -> T (in FTDALS4; dbSNP:rs770942184).
FT                                {ECO:0000269|PubMed:25803835}.
FT                                /FTId=VAR_073940.
FT   VARIANT     306    306       L -> I (in FTDALS4; unknown pathological
FT                                significance; dbSNP:rs201970436).
FT                                {ECO:0000269|PubMed:21447600,
FT                                ECO:0000269|PubMed:25943890}.
FT                                /FTId=VAR_069755.
FT   VARIANT     308    308       R -> Q (in FTDALS4; reduced kinase
FT                                activity). {ECO:0000269|PubMed:25803835}.
FT                                /FTId=VAR_073941.
FT   VARIANT     357    357       R -> Q (in FTDALS4; reduced kinase
FT                                activity; dbSNP:rs758357594).
FT                                {ECO:0000269|PubMed:25803835}.
FT                                /FTId=VAR_073942.
FT   VARIANT     388    388       N -> D (in dbSNP:rs17857028).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_024746.
FT   VARIANT     401    401       K -> E (in FTDALS4; dbSNP:rs756751089).
FT                                {ECO:0000269|PubMed:25943890}.
FT                                /FTId=VAR_073943.
FT   VARIANT     410    410       G -> R (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041211.
FT   VARIANT     464    464       V -> A (in dbSNP:rs35635889).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:21447600}.
FT                                /FTId=VAR_041212.
FT   VARIANT     559    559       M -> R (in FTDALS4; loss of kinase
FT                                activity). {ECO:0000269|PubMed:25803835}.
FT                                /FTId=VAR_073944.
FT   VARIANT     570    570       K -> Q (in dbSNP:rs17853341).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_024747.
FT   VARIANT     571    571       A -> V (in FTDALS4; dbSNP:rs765035140).
FT                                {ECO:0000269|PubMed:25803835}.
FT                                /FTId=VAR_073945.
FT   VARIANT     598    598       M -> V (in FTDALS4).
FT                                {ECO:0000269|PubMed:25803835}.
FT                                /FTId=VAR_073946.
FT   VARIANT     643    643       Missing (in FTDALS4).
FT                                {ECO:0000269|PubMed:25803835}.
FT                                /FTId=VAR_073947.
FT   VARIANT     696    696       E -> K (in FTDALS4; loss of kinase
FT                                activity; impairs binding to OPTN;
FT                                dbSNP:rs748112833).
FT                                {ECO:0000269|PubMed:25803835,
FT                                ECO:0000269|PubMed:25943890}.
FT                                /FTId=VAR_073948.
FT   MUTAGEN      30     30       K->R: Decreases ubiquitination. Abolishes
FT                                ubiquitination, phosphorylation and
FT                                kinase activity; when associated with R-
FT                                401. {ECO:0000269|PubMed:23453971}.
FT   MUTAGEN      33     33       D->A: Decreases phosphorylation and
FT                                kinase activity.
FT                                {ECO:0000269|PubMed:23453971}.
FT   MUTAGEN      38     38       K->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:10581243,
FT                                ECO:0000269|PubMed:23453971,
FT                                ECO:0000269|PubMed:23453972}.
FT   MUTAGEN     135    135       D->N: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:21931631,
FT                                ECO:0000269|PubMed:23453971,
FT                                ECO:0000269|PubMed:23453972}.
FT   MUTAGEN     172    172       S->A: Loss of kinase activity. No effect
FT                                on dimerization.
FT                                {ECO:0000269|PubMed:11839743,
FT                                ECO:0000269|PubMed:23453972}.
FT   MUTAGEN     172    172       S->E: Decreased kinase activity.
FT                                {ECO:0000269|PubMed:11839743,
FT                                ECO:0000269|PubMed:23453972}.
FT   MUTAGEN     316    316       L->E: Decreases kinase activity. No
FT                                effect on phosphorylation.
FT                                {ECO:0000269|PubMed:23453972}.
FT   MUTAGEN     325    325       Y->E: Abolishes phosphorylation and
FT                                kinase activity.
FT                                {ECO:0000269|PubMed:23453972}.
FT   MUTAGEN     355    355       E->R: Decreases phosphorylation and
FT                                kinase activity. Abolishes dimerization;
FT                                when associated with A-357 or R-448.
FT                                {ECO:0000269|PubMed:23453971,
FT                                ECO:0000269|PubMed:23453972}.
FT   MUTAGEN     357    357       R->A: Decreases phosphorylation and
FT                                kinase activity. Abolishes dimerization;
FT                                when associated with R-355.
FT                                {ECO:0000269|PubMed:23453971}.
FT   MUTAGEN     401    401       K->R: Decreases ubiquitination. Abolishes
FT                                ubiquitination, phosphorylation and
FT                                kinase activity; when associated with R-
FT                                30. {ECO:0000269|PubMed:23453971}.
FT   MUTAGEN     448    448       E->R: Decreases phosphorylation and
FT                                kinase activity. Abolishes dimerization;
FT                                when associated with R-355.
FT                                {ECO:0000269|PubMed:23453972}.
FT   MUTAGEN     459    459       H->E: Abolishes dimerization and
FT                                decreases kinase activity but no effect
FT                                on phosphorylation; when associated with
FT                                E-466 and E-470.
FT                                {ECO:0000269|PubMed:23453972}.
FT   MUTAGEN     466    466       I->E: Abolishes dimerization and
FT                                decreases kinase activity but no effect
FT                                on phosphorylation; when associated with
FT                                E-459 and E-470.
FT                                {ECO:0000269|PubMed:23453972}.
FT   MUTAGEN     470    470       F->E: Abolishes dimerization and
FT                                decreases kinase activity but no effect
FT                                on phosphorylation; when associated with
FT                                E-459 and E-466.
FT                                {ECO:0000269|PubMed:23453972}.
FT   MUTAGEN     547    547       R->D: Decreases phosphorylation and
FT                                kinase activity. Abolishes dimerization.
FT                                {ECO:0000269|PubMed:23453971}.
FT   MUTAGEN     577    577       Y->A: Decreases kinase activity.
FT                                {ECO:0000269|PubMed:23453971}.
FT   MUTAGEN     580    580       E->A: Decreases kinase activity.
FT                                {ECO:0000269|PubMed:23453971}.
FT   MUTAGEN     582    582       I->A: Decreases kinase activity.
FT                                {ECO:0000269|PubMed:23453971}.
FT   MUTAGEN     589    589       K->D: Decreases phosphorylation and
FT                                kinase activity.
FT                                {ECO:0000269|PubMed:23453971}.
FT   MUTAGEN     690    690       M->A: Decreases interaction with TANK.
FT                                {ECO:0000269|PubMed:21931631}.
FT   MUTAGEN     693    693       L->A: Almost abolishes interaction with
FT                                TANK. {ECO:0000269|PubMed:21931631}.
FT   MUTAGEN     694    694       K->E: Strongly decreases interaction with
FT                                TANK and TBKBP1. No effect on
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:21931631}.
FT   MUTAGEN     704    704       L->A: Strongly decreases interaction with
FT                                AZI2, TANK and TBKBP1. No effect on
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:21931631}.
FT   MUTAGEN     708    708       N->A: Decreases interaction with TANK.
FT                                {ECO:0000269|PubMed:21931631}.
FT   MUTAGEN     711    711       L->A: Almost abolishes interaction with
FT                                TANK. {ECO:0000269|PubMed:21931631}.
FT   STRAND        1      3       {ECO:0000244|PDB:4IM3}.
FT   STRAND        5     17       {ECO:0000244|PDB:4EUU}.
FT   STRAND       19     28       {ECO:0000244|PDB:4EUU}.
FT   TURN         29     31       {ECO:0000244|PDB:4EUU}.
FT   STRAND       34     40       {ECO:0000244|PDB:4EUU}.
FT   HELIX        42     46       {ECO:0000244|PDB:4EUU}.
FT   HELIX        49     61       {ECO:0000244|PDB:4EUU}.
FT   STRAND       65     67       {ECO:0000244|PDB:4IWO}.
FT   STRAND       70     75       {ECO:0000244|PDB:4EUU}.
FT   TURN         77     79       {ECO:0000244|PDB:4EUU}.
FT   STRAND       82     87       {ECO:0000244|PDB:4EUU}.
FT   HELIX        94     99       {ECO:0000244|PDB:4EUU}.
FT   HELIX       101    103       {ECO:0000244|PDB:4EUU}.
FT   HELIX       109    128       {ECO:0000244|PDB:4EUU}.
FT   HELIX       138    140       {ECO:0000244|PDB:4EUU}.
FT   STRAND      141    145       {ECO:0000244|PDB:4EUU}.
FT   STRAND      151    155       {ECO:0000244|PDB:4EUU}.
FT   TURN        161    163       {ECO:0000244|PDB:4IWQ}.
FT   HELIX       167    169       {ECO:0000244|PDB:4EUT}.
FT   STRAND      173    175       {ECO:0000244|PDB:4EUT}.
FT   HELIX       177    179       {ECO:0000244|PDB:4EUU}.
FT   HELIX       182    188       {ECO:0000244|PDB:4EUU}.
FT   HELIX       202    216       {ECO:0000244|PDB:4EUU}.
FT   STRAND      220    222       {ECO:0000244|PDB:4EUU}.
FT   HELIX       227    229       {ECO:0000244|PDB:4EUU}.
FT   HELIX       231    240       {ECO:0000244|PDB:4EUU}.
FT   STRAND      247    250       {ECO:0000244|PDB:4EUU}.
FT   STRAND      257    262       {ECO:0000244|PDB:4EUU}.
FT   HELIX       271    284       {ECO:0000244|PDB:4EUU}.
FT   STRAND      285    287       {ECO:0000244|PDB:4IWP}.
FT   TURN        289    291       {ECO:0000244|PDB:4EUU}.
FT   HELIX       305    307       {ECO:0000244|PDB:4EFO}.
FT   STRAND      308    315       {ECO:0000244|PDB:4EFO}.
FT   TURN        316    319       {ECO:0000244|PDB:4EFO}.
FT   STRAND      320    327       {ECO:0000244|PDB:4EFO}.
FT   HELIX       332    343       {ECO:0000244|PDB:4EFO}.
FT   HELIX       347    349       {ECO:0000244|PDB:4EFO}.
FT   STRAND      350    354       {ECO:0000244|PDB:4EFO}.
FT   STRAND      357    359       {ECO:0000244|PDB:4EFO}.
FT   HELIX       367    369       {ECO:0000244|PDB:4EFO}.
FT   STRAND      375    377       {ECO:0000244|PDB:4IM0}.
FT   STRAND      379    383       {ECO:0000244|PDB:4EFO}.
FT   HELIX       408    480       {ECO:0000244|PDB:4IM0}.
FT   HELIX       498    526       {ECO:0000244|PDB:4IM0}.
FT   STRAND      530    532       {ECO:0000244|PDB:4IWO}.
FT   HELIX       535    539       {ECO:0000244|PDB:4IM0}.
FT   HELIX       544    546       {ECO:0000244|PDB:4IM0}.
FT   HELIX       548    571       {ECO:0000244|PDB:4IM0}.
FT   HELIX       577    603       {ECO:0000244|PDB:4IM0}.
FT   HELIX       605    647       {ECO:0000244|PDB:4IM0}.
FT   TURN        648    651       {ECO:0000244|PDB:4IM0}.
FT   HELIX       680    714       {ECO:0000244|PDB:5EP6}.
FT   STRAND      715    717       {ECO:0000244|PDB:5EP6}.
SQ   SEQUENCE   729 AA;  83642 MW;  B58E4FE1B502276D CRC64;
     MQSTSNHLWL LSDILGQGAT ANVFRGRHKK TGDLFAIKVF NNISFLRPVD VQMREFEVLK
     KLNHKNIVKL FAIEEETTTR HKVLIMEFCP CGSLYTVLEE PSNAYGLPES EFLIVLRDVV
     GGMNHLRENG IVHRDIKPGN IMRVIGEDGQ SVYKLTDFGA ARELEDDEQF VSLYGTEEYL
     HPDMYERAVL RKDHQKKYGA TVDLWSIGVT FYHAATGSLP FRPFEGPRRN KEVMYKIITG
     KPSGAISGVQ KAENGPIDWS GDMPVSCSLS RGLQVLLTPV LANILEADQE KCWGFDQFFA
     ETSDILHRMV IHVFSLQQMT AHKIYIHSYN TATIFHELVY KQTKIISSNQ ELIYEGRRLV
     LEPGRLAQHF PKTTEENPIF VVSREPLNTI GLIYEKISLP KVHPRYDLDG DASMAKAITG
     VVCYACRIAS TLLLYQELMR KGIRWLIELI KDDYNETVHK KTEVVITLDF CIRNIEKTVK
     VYEKLMKINL EAAELGEISD IHTKLLRLSS SQGTIETSLQ DIDSRLSPGG SLADAWAHQE
     GTHPKDRNVE KLQVLLNCMT EIYYQFKKDK AERRLAYNEE QIHKFDKQKL YYHATKAMTH
     FTDECVKKYE AFLNKSEEWI RKMLHLRKQL LSLTNQCFDI EEEVSKYQEY TNELQETLPQ
     KMFTASSGIK HTMTPIYPSS NTLVEMTLGM KKLKEEMEGV VKELAENNHI LERFGSLTMD
     GGLRNVDCL
//
